Acadia Pharmaceuticals Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $284M | ↑+9.4% | $274M | ↑+90.3% | 6.1% |
| 2025-09-30 | $279M | ↑+11.3% | $72M | ↑+119.1% | 12.8% |
| 2025-06-30 | $265M | ↑+9.3% | $27M | ↓-20.1% | 12.2% |
| 2025-03-31 | $244M | ↑+18.7% | $19M | ↑+14.7% | 7.9% |
| 2024-12-31 | $260M | ↑+12.4% | $144M | ↑+213.9% | 59.1% |
| 2024-09-30 | $250M | ↑+18.3% | $33M | ↑+150.3% | 12.6% |
| 2024-06-30 | $242M | ↑+46.4% | $33M | ↑+2897.2% | 12.6% |
| 2024-03-31 | $206M | ↑+73.8% | $17M | ↑+138.5% | 7.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$284M
↑+9.4% +$24M YoY
Net Income
$9M
↓-93.7% -$135M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 64 quarters
margin trajectory tells the operating-leverage storyGross Margin↓-6.0pts
92.3%
Operating Margin↓-53.0pts
6.1%
Net Margin↑+41.0pts
96.3%
Go deeper
ACAD Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyACAD Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics